Skip to main content

Aliqopa Disease Interactions

There are 5 disease interactions with Aliqopa (copanlisib).

Moderate

Copanlisib (applies to Aliqopa) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Copanlisib is primarily metabolize by the liver. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild hepatic impairment. The pharmacokinetics of copanlisib have not been evaluated in patients with moderate to severe hepatic impairment. Close monitoring is recommended in these patients.

References

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc (2017):
Moderate

Copanlisib (applies to Aliqopa) hyperglycemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Hyperglycemia has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood glucose control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistent of hyperglycemia. Diabetic patients should only be treated with this agent following adequate glucose control and should be monitored closely.

References

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc (2017):
Moderate

Copanlisib (applies to Aliqopa) hypertension

Moderate Potential Hazard, Moderate plausibility.

Hypertension has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood pressure control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of hypertension. It is recommended to monitor blood pressure before and after the infusion with copanlisib.

References

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc (2017):
Moderate

Copanlisib (applies to Aliqopa) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Immunodeficiency, Bone Marrow Depression/Low Blood Counts, Interstitial Pneumonitis

Serious infections, including infections and non-infectious pneumonitis, have occurred in patients treated with copanlisib. Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of jiroveci pneumonia infection. It is recommended to monitor patients closely according to medical practice and for signs and symptoms of infection and to treat as medically appropriate. The dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of symptoms.

References

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc (2017):
Moderate

Copanlisib (applies to Aliqopa) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Copanlisib undergoes minimal renal elimination. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment. The pharmacokinetic copanlisib has not been evaluated in patients with severe renal impairment or in those patients with end stage renal disease with or without dialysis. Close monitoring is recommended in these patients.

References

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc (2017):

Aliqopa drug interactions

There are 322 drug interactions with Aliqopa (copanlisib).

Aliqopa alcohol/food interactions

There are 2 alcohol/food interactions with Aliqopa (copanlisib).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer